Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG.APV-527 in advanced solid tumors
NCT05934539Phase 2Recruiting
- Sponsor
- Aptevo Therapeutics
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ALG.APV-527 in solid tumor, non-small cell lung cancer (NSCLC), gastric cancer (GC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), sponsored by Aptevo Therapeutics. Started Dec 2022; status: recruiting.
02
Drugs
ALG.APV-527
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastric cancer (GC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05934539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934539.